Tandem Diabetes SEC Filings

Susan M. Morrison, EVP & Chief Administrative Officer of Tandem Diabetes Care, Inc. (TNDM), reported equity transactions dated 08/15/2025 on Form 4. The filing shows vesting of restricted stock units (RSUs) awarded under the 2023 Long-Term Incentive Plan: 1,503 RSUs and 1,097 RSUs were settled (transaction code M) with an acquisition price of $0 for each award. To satisfy tax withholding on the vesting, the company withheld 430 and 314 shares respectively at a withholding price of $10.82 per share; the filer states explicitly that no shares were sold. The Form indicates the transactions were reported by an attorney-in-fact on 08/19/2025. The filing itemizes the share movements and confirms the RSU grant and vesting schedule terms referenced in the explanation section of the Form.

John F. Sheridan, President & CEO and director of Tandem Diabetes Care, Inc. (TNDM), reported RSU vesting and related share withholding to cover taxes on transactions dated 08/15/2025. The filing shows vested restricted stock units (RSUs) settled into 5,471 and 5,982 shares respectively, increasing underlying ownership; the company withheld 2,779 and 3,038 shares in two separate withholding dispositions at $10.82 per share to satisfy tax obligations. After these transactions, Sheridan beneficially owned between 109,019 and 115,001 shares across reported lines. The RSUs were awarded under the 2023 Long-Term Incentive Plan and vest per the schedules described in the filing.

Rick A. Carpenter, Chief Technology Officer of Tandem Diabetes Care, Inc. (TNDM), reported multiple equity transactions on 08/15/2025. Two grants of restricted stock units (RSUs) vested, resulting in 1,437 and 898 shares being issued at $0 as part of long-term incentive awards. To satisfy tax withholding on vesting, the company withheld 730 and 457 shares; the withheld shares were not sold. After the reported transactions, the filing shows common stock beneficial ownership balances changing between 21,926 and 22,824 shares and derivative (RSU) balances of 4,311 and 6,281 shares as reported in the table. The RSUs were awarded under the 2023 Long-Term Incentive Plan and vest on a 33% initial schedule with subsequent quarterly installments.

Leigh A. Vosseller, EVP & Chief Financial Officer of Tandem Diabetes Care, Inc. (TNDM), reported multiple transactions on 08/15/2025 related to vested restricted stock units (RSUs) and tax-withholding events. The filing shows two RSU vesting events that resulted in the acquisition of 1,503 and 1,495 shares each (total 2,998 shares) at $0 price upon vesting, increasing her direct holdings. The report also records share withholdings to satisfy tax obligations: 538 and 535 shares withheld at $10.82 per share. Following the transactions, total directly held common stock positions reported are 4,509 and 10,469 shares tied to two RSU awards, and 35,723–36,258 shares in various lines; additionally, 25,580 shares are held indirectly in the Leigh A. Vosseller Trust. The form was signed by an attorney-in-fact on 08/19/2025.

Tandem Diabetes Care insider Shannon M. Hansen reported multiple transactions on 08/15/2025 related to restricted stock units (RSUs) and common stock. The filing shows vesting-driven acquisitions: 531, 1,437 and 1,097 RSUs converted into common stock (total underlying 3,065 shares added to direct holdings) and corresponding increases in direct common stock ownership to a reported 7,677 shares of derivative-backed common stock and 19,102 shares of direct common stock at various steps. Several entries show shares withheld to satisfy tax withholding at $10.82 per share; no open-market sales were reported. The securities held indirectly are in the Shannon M. Hansen Trust.

Elizabeth A. Gasser, EVP and Chief Strategy Officer of Tandem Diabetes Care, reported multiple transactions on 08/15/2025 affecting her holdings of TNDM common stock. She acquired 1,503 shares (RSU vesting) and an additional 1,097 shares (RSU vesting), both reported as acquisitions at $0 per share. To satisfy tax withholding on vesting, 805 and 588 shares were withheld and disposed at $10.82 per share; no shares were sold on the open market. She directly beneficially owns 4,509 shares from vested RSUs and 7,677 shares from other RSUs per the table, and indirectly holds 22,949 shares through The Gasser Family Trust, where she is a co-trustee.

John F. Sheridan, President & CEO and director of Tandem Diabetes Care, Inc. (TNDM), reported a non-derivative purchase of 10,000 shares on 08/11/2025. The filing states the trades executed at prices ranging from $10.19 to $10.33, with a weighted average purchase price of $10.2318. Following the reported transaction, the reporting person beneficially owned 106,327 shares.

The Form 4 identifies the filing as by one reporting person and includes an explanatory note that full details of the multiple trades (number of shares per trade and individual prices) will be provided upon request. The form is signed by Rachel Malina as attorney-in-fact for John F. Sheridan.

Insider Form 4 for Tandem Diabetes Care (TNDM)

Leigh Vosseller, EVP & Chief Financial Officer, reported a purchase of 13,720 shares of Tandem common stock on 08/08/2025 at a weighted average price of $10.8895. The filing states the trades were executed in multiple trades at prices ranging from $10.86 to $10.90. The report also shows a reported disposition of 33,798 shares (table entry lists the amount as a disposition without a transaction date or price). The filing notes that certain securities are held by the Leigh A. Vosseller Trust dated January 17, 2010, for which Ms. Vosseller is trustee, and lists 25,580 shares as beneficially owned following the reported transaction(s).